CJC/IPA 10mg

CJC-1295 (No DAC) and Ipamorelin are two highly complementary research peptides frequently studied together for their synergistic effects on the growth hormone (GH) axis. By targeting distinct yet interconnected regulatory pathways, this peptide combination provides researchers with a valuable model for investigating endogenous growth hormone secretion, endocrine signaling, metabolic regulation, and age-related physiological processes.

CJC-1295 (No DAC) is a modified analog of Growth Hormone Releasing Hormone (GHRH) that stimulates GHRH receptors within the anterior pituitary gland, promoting the natural release of growth hormone in a physiologically relevant pulsatile pattern. Unlike its DAC-modified counterpart, CJC-1295 (No DAC) possesses a shorter duration of activity, making it particularly useful for studying acute growth hormone signaling and receptor dynamics.

Ipamorelin is a highly selective Growth Hormone Secretagogue Receptor (GHS-R1a) agonist that mimics the activity of ghrelin, stimulating growth hormone release through an independent pathway. Its receptor specificity and minimal influence on other pituitary hormones have made it a preferred compound for investigating growth hormone physiology without broad endocrine disruption.

When utilized together, CJC-1295 (No DAC) and Ipamorelin provide dual-pathway stimulation of growth hormone secretion through both GHRH and ghrelin receptor activation. This coordinated mechanism has generated significant interest in studies examining pulsatile growth hormone release, insulin-like growth factor-1 (IGF-1) signaling, protein synthesis, tissue recovery, metabolic efficiency, and cellular adaptation.

Researchers have explored this peptide combination in models related to body composition, exercise physiology, recovery biology, healthy aging, and endocrine regulation. The ability to stimulate endogenous growth hormone production through complementary pathways offers a valuable framework for understanding the complex interactions between hormonal signaling, metabolism, and cellular repair mechanisms.

As scientific interest in peptide-based endocrine research continues to expand, the combination of CJC-1295 (No DAC) and Ipamorelin remains a cornerstone model for investigating growth hormone physiology, metabolic resilience, recovery processes, and the biological pathways associated with long-term health and vitality.

CJC-1295 (no DAC)
CAS NO: 863288-34-0
Molecular Formula: C152H252N44O42
Molecular Weight: 3367.9 g/mol

Ipamorelin
CAS NO: 170851-70-4
Molecular Formula: C38H49N10O
Molecular Weight: 711.9 g/mol

Appearance: White Powder

Research Use Only
This product is intended solely for in vitro laboratory research purposes. It is not approved for human or animal use and must not be used in food, dietary supplements, pharmaceuticals, or cosmetic applications. All products arrive in lyophilized (freeze-dried) powder form.

Legal Disclaimer
This product and any associated information have not been evaluated by the U.S. Food and Drug Administration (FDA). No representations or warranties are made regarding its use for the diagnosis, treatment, cure, or prevention of any disease. Use is strictly limited to qualified professionals operating in properly equipped and certified laboratory environments.

Terms of Sale
By purchasing from Cutting Edge Compounds, the buyer certifies that they are a qualified researcher or represent a licensed institution. The buyer assumes full responsibility for ensuring compliance with all applicable laws and regulations governing the purchase, handling, storage, and use of this product. All sales are final.